Sofie Emilie Hagelund • Henrique Gomes • Paula Meerjanssen • Shuyue Zhang • Eszter Hudra
MAQC-II Project: human breast cancer (BR) dataset
- Breast cancer patients are mainly white and between the ages of 40-59.
There is no clear correlation between age and genotype.
ER+ patients have the worst treatment response
Treatment response does not correlate with tumor aggressiveness
Treatment response does not correlate with tumor size
Most of the genotypes have a tumor size of 2, or developed into size 3-4. Especially the case for:
Treatment response does not correlate with lymph node involvement
Generally, following genotypes have the most lymph node involvement:
ER+, PR-, HER2-
ER-,PR-, HER2+
ER-, PR-, HER2- (triple negative)
More treatment options lead to better response
The last two groups were exposed to the most different treatment options:
A general broad TFAC and TFEC is not working for ER+ patients.
More personalized treatment options give better response.
The level of aggressiveness, tumor size, and lymph node involvement do not necessarily mean a bad response if personalized treatment is an option.
We are happy to answer any of your questions!
Shi L. Gene expression data from 230 stage I–III breast cancers (GSE20194). NCBI Gene Expression Omnibus. GEO Series GSE20194. Accessed via https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE20194